Niemeyer Philipp, Laute Volker, Zinser Wolfgang, Becher Christoph, Kolombe Thomas, Fay Jakob, Pietsch Stefan, Kuźma Tomasz, Widuchowski Wojciech, Fickert Stefan
Department of Orthopedics and Trauma Surgery, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
OCM Clinic, Munich, Germany.
Orthop J Sports Med. 2019 Jul 10;7(7):2325967119854442. doi: 10.1177/2325967119854442. eCollection 2019 Jul.
Autologous chondrocyte implantation (ACI) and microfracture are established treatments for large, full-thickness cartilage defects, but there is still a need to expand the clinical and health economic knowledge of these procedures.
To confirm the noninferiority of ACI compared with microfracture.
Randomized controlled trial; Level of evidence, 2.
Patients were randomized to be treated with matrix-associated ACI using spheroid technology (n = 52) or microfracture (n = 50). Both procedures followed standard methods. Patients were assessed by the Knee injury and Osteoarthritis Outcome Score (KOOS), MOCART (magnetic resonance observation of cartilage repair tissue) scoring system, Bern score, modified Lysholm score, International Cartilage Repair Society (ICRS) rating (histological and immunochemical scoring after rebiopsy 24 months after implantation), and International Knee Documentation Committee (IKDC) examination form. The main assessments were conducted 24 months after study treatment.
In the primary intention-to-treat analysis, the overall KOOS score for both ACI and microfracture yielded a statistically significant improvement relative to baseline. According to the between-group analysis, ACI passed the test of noninferiority compared with microfracture; thus, the primary goal of the study was achieved. The KOOS subscores yielded the same qualitative results as the overall KOOS score (ie, for each of these, noninferiority was demonstrated), and in 1 case (Activities of Daily Living subscore), the threshold for superiority was passed. The subgroup analyses did not yield any clear evidence of an association between treatment effect and any of the categories investigated (age, diagnosis, defect localization, sex). A histological analysis of biopsies from 16 patients (ACI: n = 9; microfracture: n = 7) suggested a better quality of repair in the patients treated with ACI.
The efficacy of both ACI and microfracture was demonstrated with respect to both functional outcomes and morphological repair. The primary analysis confirmed the statistical hypothesis of the noninferiority of ACI, even for relatively small cartilage defects (1-4 cm) treated in this study, the indication for which microfracture is generally accepted as the standard of care. ACI showed significant superiority in the KOOS subscores of Activities of Daily Living at 24 months and Knee-related Quality of Life at 12 months.
NCT01222559 (ClinicalTrials.gov identifier).
自体软骨细胞移植(ACI)和微骨折术是治疗大面积全层软骨缺损的既定疗法,但仍需拓展这些手术的临床及卫生经济学知识。
证实ACI相较于微骨折术的非劣效性。
随机对照试验;证据等级,2级。
患者被随机分为接受使用球体技术的基质相关ACI治疗组(n = 52)或微骨折术治疗组(n = 50)。两种手术均遵循标准方法。通过膝关节损伤和骨关节炎结局评分(KOOS)、MOCART(软骨修复组织磁共振观察)评分系统、伯尔尼评分、改良Lysholm评分、国际软骨修复协会(ICRS)评级(植入后24个月再次活检后的组织学和免疫化学评分)以及国际膝关节文献委员会(IKDC)检查表对患者进行评估。主要评估在研究治疗后24个月进行。
在主要的意向性分析中,ACI组和微骨折术组的总体KOOS评分相对于基线均有统计学显著改善。根据组间分析,ACI相较于微骨折术通过了非劣效性检验;因此,研究的主要目标得以实现。KOOS子评分产生了与总体KOOS评分相同的定性结果(即,对于每一项子评分,均证明了非劣效性),并且在1例(日常生活活动子评分)中,达到了优效性阈值。亚组分析未产生任何明确证据表明治疗效果与所研究的任何类别(年龄、诊断、缺损部位、性别)之间存在关联。对16例患者(ACI组:n = 9;微骨折术组:n = 7)活检样本的组织学分析表明,接受ACI治疗的患者修复质量更好。
ACI和微骨折术在功能结局和形态修复方面均显示出疗效。主要分析证实了ACI非劣效性的统计学假设,即使对于本研究中治疗的相对较小的软骨缺损(1 - 4厘米),微骨折术通常被认为是标准治疗方法。ACI在24个月的日常生活活动KOOS子评分和12个月的膝关节相关生活质量方面显示出显著优效性。
NCT01222559(ClinicalTrials.gov标识符)